In vivo mode of action of CYC116, a novel small molecule inhibitor of Aurora kinases and VEGFR2

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Research

• Publication date

  2008-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Aurora kinases signaling in cancer: from molecular perception to targeted therapies

  2025cites this paper
• Exploring a novel thiazole derivatives hybrid with fluorinated-indenoquinoxaline as dual inhibitors targeting VEGFR2/AKT and apoptosis inducers against hepatocellular carcinoma with docking simulation.

  2024cites this paper
• An Anti-Cancer Drug Candidate CYC116 Suppresses Type I Hypersensitive Immune Responses through the Inhibition of Fyn Kinase in Mast Cells

  2018cites this paper
• Aurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review

  2015cites this paper
• Aurora kinase inhibitors: Progress towards the clinic

  2012influential citation
• Pharmacodynamic Modelling of Biomarker Data in Oncology

  2012cites this paper
• ENMD-2076 for hematological malignancies

  2012cites this paper
• Update on aurora kinase targeted therapeutics in oncology

  2011cites this paper
• An integrated pharmacokinetic–pharmacodynamic model for an Aurora kinase inhibitor

  2010cites this paper
• Aurora A and B kinases--targets of novel anticancer drugs.

  2010cites this paper
• Aurora kinase inhibitors in preclinical and clinical testing

  2009cites this paper
• Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

  2009cites this paper
• Cancer Therapy: Clinical A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

  2009cites this paper
• Discovery and development of aurora kinase inhibitors as anticancer agents.

  2009cites this paper
• A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

  2009cites this paper